Unicycive Therapeutics Inc (UNCY)

$0.37

+0.01

(+3.12%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $0.35
    $0.38
    $0.37
    downward going graph

    4.7%

    Downside

    Day's Volatility :6.84%

    Upside

    2.25%

    downward going graph
  • $0.20
    $1.82
    $0.37
    downward going graph

    45.41%

    Downside

    52 Weeks Volatility :88.89%

    Upside

    79.65%

    downward going graph

Returns

PeriodUnicycive Therapeutics IncIndex (Russel 2000)
3 Months
-25.24%
0.0%
6 Months
-69.67%
0.0%
1 Year
-56.32%
0.0%
3 Years
-86.19%
-20.8%

Highlights

Market Capitalization
34.9M
Book Value
- $0.34
Earnings Per Share (EPS)
-0.36
Wall Street Target Price
5.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-53.37%
Return On Equity TTM
-121.76%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-28.8M
Diluted Eps TTM
-0.36
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.73
EPS Estimate Next Year
-0.2
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.18

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Unicycive Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
9
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1318.92%

Current $0.37
Target $5.25

Technicals Summary

Sell

Neutral

Buy

Unicycive Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Unicycive Therapeutics Inc
Unicycive Therapeutics Inc
-2.63%
-69.67%
-56.32%
-86.19%
-93.68%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.78%
12.27%
21.13%
86.55%
232.53%
Novo Nordisk A/s
Novo Nordisk A/s
-12.16%
-3.59%
19.82%
145.88%
361.43%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.63%
91.46%
72.01%
39.76%
259.26%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.64%
21.48%
30.9%
167.3%
177.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Unicycive Therapeutics Inc
Unicycive Therapeutics Inc
NA
NA
NA
-0.73
-1.22
-0.53
NA
-0.34
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.88
26.88
1.38
45.01
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.83
40.83
1.8
3.37
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.38
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Unicycive Therapeutics Inc
Unicycive Therapeutics Inc
Buy
$34.9M
-93.68%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.1B
232.53%
26.88
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$523.9B
361.43%
40.83
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
259.26%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.3B
177.5%
32.84
-4.74%

Insights on Unicycive Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 951.0K → -271.0K (in $), with an average decrease of 84.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -20.96M → 3.93M (in $), with an average increase of 633.4% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.0% return, outperforming this stock by 128.3%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.8% return, outperforming this stock by 126.0%

Institutional Holdings

  • Logos Global Management LP

    7.36%

  • Nantahala Capital Management, LLC

    5.98%

  • Vivo Capital, LLC

    3.68%

  • RA Capital Management, LLC

    2.79%

  • Bvf Inc

    2.33%

  • Rosalind Advisors, Inc.

    1.67%

Company Information

unicycive therapeutics is passionate about treating kidney diseases with significant unmet medical needs.

Organization
Unicycive Therapeutics Inc
Employees
14
CEO
Dr. Shalabh K. Gupta M.D., MPA
Industry
Miscellaneous

Discover More

FAQs